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Abstract 
 
Objective: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by 
multiple organ involvement due to the vascular deposition of immune-complexes, mainly the 
cryoglobulins. B-lymphocyteexpansion represents the underlying pathological alteration 
frequently triggered by hepatitis C virus (HCV) infection. The treatment of MCs syndrome is 
generally based on antiviral drugs and/or immunosuppressors, among which rituximab, an anti-
CD20 monoclonal antibody, has been usefully employed for both cutaneous and visceral MCs 
organ involvement. This multicenter study retrospectively evaluated the effects of rituximab in a 
large series of patients with active MCs. The observed results were compared to those emerging 
from the updated review of the literature on this topic.  
Methods: The study included 87 patients (male/female 19/68, mean age 62.3±11.4SD years, 
mean disease duration 9±6.2SD years, HCV infection in 92% of cases) with active 
cryoglobulinemic vasculitis evaluated before rituximab monotherapy and after 6-month follow-up 
by means of main clinico-serological parameters. A PubMed search up to May 31, 2011, was 
done to find published clinical studies, including case reports of MCs treated with rituximab.  
Results: A significant clinical improvement was observed in a relevant percentage of cases, 
regardless the presence/absence of associated HCV infection; namely, complete/partial remission 
of pre-treatment active manifestations was observed in 74% of skin purpuric lesions, up to 87% of 
non-healing vasculitic leg ulcers, and 44% of the peripheral neuropathy, mainly paresthesias 
(patient's visual analo
nephropathy, observed in 38 patients, significantly improved in 95% of cases (serum creatinine 
-hour proteinuria from 2.2±2.1SD to 
0.9±1.7SD 
complicating non-Hodgkin's B-cell lymphoma a complete or partial remission was observed in 
5/6. A complete remission of abdominal vasculitis was also observed in one patient. These 
beneficial effects were mirrored by the improvement of cryoglobulinemic serological hallmarks, 
namely cryocrit and low complement C4, in half cases.  
The safety of rituximab was confirmed by the small number of side effects recorded during the 6-
month follow-up. On the whole, the results of the present study are in keeping with those reported 
in 39 papers present in world literature, including a total of 279 MCs patients.  
Conclusions: Rituximab may be regarded as useful and safe pathogenetic treatment of 
cryoglobulinemic vasculitis. The actual role of this drug should be definitely confirmed by 
randomized controlled trials, as well as its position in the therapeutical strategy, mainly with 
respect to antiviral treatment in HCV-associated MCs. 
 
1. Introduction  
 
Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by multiple organ 
involvement due to the vascular deposition of immune-complexes, mainly mixed IgG-IgM 
cryoglobulins and complement [1-3]. These cryoprecipitable immune-complexes are the result of 
B-cell clone proliferation producing pathogenic IgM with rheumatoid factor activity. In the 
majority of cases the B-cell expansion is triggered by chronic hepatitis C virus (HCV) infection; 
the HCV lymphotropism is responsible for the immune-system alterations underlying the MCs 
[3,4]. Clinically, the disease may present with variable symptom composition ranging from mild 
MCs (purpura, arthralgia, and asthenia) to more serious manifestations; namely, neurological, 
renal, hepatic, and/or wide spread vascular involvement [1-5]. Patients with mild manifestations 
are generally responsive to symptomatic treatments; while, moderate-severe symptoms may 
deserve more aggressive approach with etiological and/or pathogenetic therapies, in particular 
antiviral or immunosuppressive drugs [5-7]. Considering the rarity of the disease in general and of 
clinically homogeneous patients' with active, severe cryoglobulinemic vasculitis, data regarding 
etio-pathogenetic treatments are generally limited to small patients' series [6]. The combination of 
pegylated interferon-alpha with ribavirin may represent the first-choice treatment for more 
stabilized patients with ongoing HCV infection complicated by severe organ involvement, 
especially when associated to active chronic hepatitis [7,8].  
The antiviral treatment may be limited by frequent poor tolerability and/or responsiveness, 
including the low rate of HCV eradication, observed in a not negligible number of patients [5,6]; 
in these cases, as well as in very active cases, and obviously in HCV- negative individuals the 
pathogenetic treatments, namely corticoste- roids, cyclophosphamide, and/or plasmapheresis, 
represent the standard approach to cryoglobulinemic vasculitis, firstly proposed in the pre-HCV 
decades [5]. These therapies may be responsible for serious, seldom life-threatening 
complications; therefore, the management of patients with MCs is often particularly difficult 
[5,6]. Since 1999 anecdotal observations followed by two pilot studies showed the efficacy and 
safety of anti-CD20 monoclonal antibody (rituximab) treatment in patients with cryoglobulinemic 
vasculitis, often resistant or intolerant to other therapies [9-12]. The safety and efficacy of this 
drug have been reported in various vasculitides and other systemic autoimmune diseases [13-23]. 
The usefulness of monoclonal antibodies directed to CD20 antigen, a trans membrane protein 
expressed on pre-B lymphocytes and mature B lymphocytes, on both cutaneous and visceral 
organ involvement of MCs, including low grade B-cell lymphoma, has been reported by various 
Authors, generally referred to small patients' series [24-31]. These are often characterized by a 
heterogeneous composition of clinical manifestations that does not permit an accurate evaluation 
of the effect of rituximab on single organ involvement. In the present multicenter study we 
retrospectively analyzed a large series of patients with cryoglobulinemic vasculitis treated with 
rituximab; moreover, we compared the observed clinical results with those emerging from the 
updated review of the literature on the same topic. 
 
 
2. Patients and methods  
 
A series of 87 patients with active cryoglobulinemic vasculitis (male/female 19/68, mean age 62.3 
± 11.4SD years, mean disease duration 9 ± 6.2SD years) were enrolled for this multicenter retro- 
spective study (Table 1). The patients recruited have been recently treated with rituximab but 
never described in previous reports. In all cases the MCs classification satisfied the recently 
proposed criteria [32]; concomitant autoimmune systemic diseases or malignancies were 
invariably ruled-out, as well as possible infectious conditions other than HCV. The possible 
association with hepatotropic virus infection, i.e. HCV and HBV, was investigated by detection of 
specific serum antibodies and viremia. Both clinical and laboratory parameters were carefully 
evaluated according to standard methodologies as previously described [3,5,33]. At the time of 
the rituximab treatment, the patients showed a variable combination of MCs clinical 
manifestations (Table 1); namely, cutaneous symptoms, mainly purpura and skin ulcers, 
peripheral sensory-motor neuropathy, renal involvement, chronic hepatitis, widespread vasculitic 
syndrome, and/or B-cell lymphoma. In all cases the presence of clinically advanced cirrhosis 
and/or hepatocellular carcinoma was excluded. Laboratory investiga- tions comprised serum 
cryoglobulin detection (cryocrit) and compo- sition, rheumatoid factor determination, routine 
blood chemistry, and urinalysis [5]. When clinically required organ involvement (skin, kidney, 
liver, and/or bone marrow) was further investigated by means of ultrasonography and/or bioptical 
tissue examination. The effects of treatment were evaluated by comparing clinical and 
immunological parameters before rituximab cycle and at first 6 month follow-up. Clinical 
response to treatment was defined by evaluating the following main clinical signs: vasculitic skin 
involvement (variations of purpura score and/or dimensions of ulcerative lesions), peripheral 
sensory or sensory-motor neuropathy (clinical and/or electrophysiological changes), renal 
involvement (variations of serum creatinine level and/or 24-hour proteinuria), B-cell lymphoma 
(clinical symptoms and bone marrow infiltrate changes) [5]. Therapeutical effects of rituximab 
were defined as a) complete response (CR) for disappearance of baseline main manifestation(s), 
no responders (NR) for absent or insufficient response (improvement b50%) [34]. The relapse of 
MCs was defined as the reappearance of at least one of pre-treatment clinical signs of MCs during 
the first 6-month follow-up. For immunological parameters, a complete response of cryocrit was 
defined by the disappearance of serum cryoglobulins, while a partial response for a cryocrit 
decrease of more than 50% from the baseline level; in patients with abnormally reduced C4 
(below lower limit of normal range), a complete response was referred to the C4 normalization 
and a partial response to increased C4 levels without normalization. 
Severe adverse events attributable to rituximab were defined as an adverse event that occurred 
during infusion sessions or within the first 12 months following the treatment and that required 
hospitalization and/or resulted in death (or that required intravenous antibiotics in case of 
infection) [34]. Statistical analysis was carried out by means of non-parametrical Wilcoxon test to 
evaluate the variations before/after rituximab treatment.  
 
 
3. Review of the literature 
 
A PubMed search up to 31 May 2011, with the key words 'cryoglobulinemia', 'cryoglobulinemic 
vasculitis', 'rituximab', and 'anti-CD20', was done to find published clinical studies, including case 
reports of MCs treated with rituximab. Review papers were excluded. A total of 39 manuscripts 
that reported on at least one case of cryoglobulinemic vasculitis treated with rituximab were 
included in the present analysis [9-12,24-31,34-60]. Three manuscripts were excluded because 
they included patients that had already been described in other publications [9,11,37].  
  
4. Results  
 
The baseline clinico-epidemiological features of 87 patients with MCs undergoing rituximab 
treatment are shown in Table 1. HCV- related MCs was present in the large majority of cases 
(92%), while the so-called 'essential' MCs was present in only 5 (6%) patients; only 2 individuals 
showed MCs overlapping with other connective tissue diseases (Sjogren's syndrome in both 
cases). The treatment with rituximab was decided because of non-responsiveness or intolerance to 
other previous treatments; in only 13 (15%) patients rituximab was administered as first-line 
therapy for cryoglobulinemic syndrome. The main indications to rituximab were a 
membranoproliferative glomerulonephritis (MPGN) in 30% of cases, peripheral neuropathy in 
23%, and severe skin vasculitis, including non-healing ulcers, in 25%; while 14% of individuals 
showed multiple active manifestations (Table 1). The administration schedule of rituximab 
comprised two (1 g × 2 every other week in 18 pts) or four sessions of intravenous infusions (375 
mg/m2/week × 4 in 59 pts); while 10 patients received a cycle of 6 infusions (375 mg/m2/week × 
4 + 375 mg/m2 monthly for 2 months). Antiviral therapy had been previously administered to 44 
(50.6%) patients, and was suspended at least 6 months before rituximab administration. 
Concomitant treatments to rituximab were only glucocorticoids, when needed. Efficacy data were 
analyzed 6 months after rituximab treatment.  
At the end of 6-month follow-up, the overall patients' evaluation showed a clear-cut clinical 
improvement in a relevant percentage of cases. In particular, CR of pre-treatment active 
manifestations was frequently observed, varying from the 44% of the peripheral neuropathy to 
74% of purpuric lesions. Skin manifestations of cryoglobulinemic vasculitis were particularly 
responsive to rituximab treatment; namely, non-healing vasculitic leg ulcers gradually recovered 
or improved in 87% of cases. Among the most harmful complications of the disease, MPGN 
improved in the large majority of patients (95%), with complete remission in 50% (normalization 
of serum creatinine and absence of significant proteinuria). Fig. 1 shows the significant decrease 
-hour proteinuria 
(from 2.2 ± 2.1SD to 0.9 ± 1.7
due to peripheral sensory neuropathy evaluated by patient's visual analogical scale (from 62 ± 25 
-Hodgkin's B-cell lymphoma a 
complete or partial remission was observed in 5/6. The patient with abdominal vasculitis showed 
a complete remission of this life-threatening clinical manifestation.  
Finally a complete/partial response of cryoglobulinemic serolog- ical hallmarks, namely cryocrit 
and low complement C4, was observed in half cases (Table 2).  
A relatively small number of side effects were recorded after rituximab treatment (Table 2).  
In particular, infusion-related reactions were observed in 4 patients, i.e. hypotension (2), urticaria 
(1), and serum sickness-like reaction (1). During the 6-month follow-up four patients developed 
infectious complications, including urinary tract infection (2), infectious pneu- monia (1), and 
gangrene (1) or mild/transient symptoms such as neutropenia (2), hypogammaglobulinemia (5), 
hypertransaminasemia (1). Three patients experienced severe adverse events, namely infectious 
pneumonia, gangrene, and the above mentioned serum sickness-like reaction. For these reasons, 
these three patients dropped- out; another patient discontinued the treatment due to worsening of 
vasculitis.  
On the whole, rituximab might be considered responsible for disease worsening in only 2/87 
(2.2%) patients; one developed a severe peripheral neuropathy, the other one showed a worsening 
of necrotizing skin vasculitis.  
 
5. Review of the literature  
 
Including the first single case report described by Zaja et al. in 1999 [9-12,24-31,34-60], a total of 
40 manuscripts that reported on at least one case of cryoglobulinemic vasculitis treated with 
rituximab were considered in the present analysis (Table 3). Besides the present case series, Table 
3 includes a total of 279 patients with MCs described between 1999 and 2011; it regards 
numerous case reports and 16 clinical studies with at least 5 patients treated with rituximab (Table 
3). No controlled clinical trials have been published to date, with the exception of one recent 
study [61]. There is a great inhomogeneity among different series of patients treated with 
rituximab as regards to both previous therapeutical approaches and indications to treatment. In 
this respect, the most frequent manifes- tations needing rituximab therapy were skin vasculitis, 
peripheral neuropathy, and renal involvement. The majority of patients (84.8%) showed HCV-
associated cryoglobulinemic vasculitis, often character- ized by type II mixed cryoglobulinemia 
(88%). The cumulative dosage of rituximab cycles and treatment modalities were quite uniform; 
generally the schedule included four consecutive intravenous in- fusions of 375 mg/m2/week of 
rituximab (69%). In 3 recent studies [26,29,30], the rituximab was associated to antiviral therapy 
(Peg- interferon-alpha + ribavirin), while in one with other immunosup- pressive or antiblastic 
drugs [34] (Table 3). After the first 6-month follow-up, a clear-cut clinical improvement of main 
cryoglobulinemic manifestations was observed in the majority of cases (Table 3). With the 
limitations due to the above mentioned inhomogeneity among treated patients' series, the 
cumulative analysis of previous studies reporting detailed therapeu- tical effects showed a CR or 
PR for skin vasculitis in 106/117 (94%), skin ulcers in 32/36 (89%), peripheral neuropathy in 
85/89 (95%), renal involvement in 46/52 (88%), B-NHL in all reported cases, and remission of 
abdominal vasculitis in 7/8 (87%) patients. Severe adverse effects possibly related to anti-CD20 
treatment were recorded in 18/252 (7%) subjects (Table 3).  
 
6. Discussion  
 
This multicenter, retrospective study including a large patients' series further supports and 
expands the results of previous reports showing the usefulness of rituximab in active MCs [9-
12,24-31,34- 60]. The positive effects of this treatment were particularly evident for the most 
frequent disease manifestations such cutaneous vasculitic lesions, i.e. severe purpura and/or non-
healing ulcers, and peripheral neuropathy, often resistant to traditional treatments. Moreover, the 
number of patients recruited permitted to better evaluate the effects of anti-CD20 therapy on other 
less frequent complications, such as renal involvement that represents a harmful visceral 
complication of cryoglobulinemic vasculitis [1-3,5,33]. The large majority of individuals (95%) 
showed a complete or partial remission of MPGN at 6-month follow-up from rituximab cycle. On 
the whole, the significant clinical improvement was mirrored by the positive variations of 
serological MCs hallmarks in half cases; namely, the reduction of circulating cryoglobulin levels 
and/or the increase/ normalization of complement C4. Together with the high percentage of 
patients responsive to rituximab, the low rate of side effects confirmed the safety of this drug, 
during the treatment sessions as well as the entire 6-month follow-up. This was also the case of 
liver damage; the absence of any signs of hepatic toxicity is remarkable considering the 
association of MCs with chronic HCV infection in the large majority of patients (92%). In this 
respect, previous studies clearly demonstrated that, when present, the increase of HCV viral load 
did not affect the liver texts as well as other clinico-serological parameters [11,12]. The lack of 
hepatic toxicity has been further evidenced by a recent clinical observation in patients with HCV-
related MCs and advanced cirrhosis treated by rituximab [29,49]; besides its efficacy on 
cryoglobulinemic vasculitis the treatment was followed by an improvement of liver function. It is 
possible to ascribe this unexpected hepatic amelioration to the depletion of CD20+ B-cells 
induced by rituximab through two different mechanisms; firstly, the drug may reduce also the 
hepatic B-cell infiltrates conditioning liver damage and, indirectly, it may improve the Kupffer 
cell function as consequence of serum cryoglo- bulin level reduction [28]. Apart from the efficacy 
and the long-term safety of rituximab, Sène and Colleagues reported a significant number of 
systemic reactions after the drug infusion [62]. In HCV-related cryoglobulinemic vasculitis, 
rituximab may form a complex with RF-positive IgM, responsible for accelerated 
cryoprecipitation and severe systemic reactions. To avoid such harmful infusion-related 
complication, rituximab should be administered with caution in cryoglobulinemic vasculitis [62]. 
Even if serum sickness has been rarely observed in the large majority of studies with rituximab in 
MCs [6], French authors suggested the use of protocol with four weekly consecutive intravenous 
infusions of 375 mg/m2 of rituximab, possibly associated with plasmapheresis prior to rituximab 
infusion, mainly in patients with high baseline levels of mixed cryoglobulins [62]. However, we 
observed a low rate of infusion-related complications, both in patients treated with this regimen, 
and in patients treated with different rituximab schedule of 1 gram every two weeks (two 
infusions in total).  
The natural history of MCs is unpredictable and strongly depends on the severity of disease 
complications and co-morbidities, as well as the response to available treatments. Morbidity due 
specifically to cryoglobulinemic syndrome may also be significant; it may be related to infections, 
cardiovascular diseases, progressive renal failure, and advanced neuropathy [5]. The overall 
prognosis is worse in patients with renal disease, liver failure, lymphoproliferative disease, and 
malignancies [5]. Therefore, a careful monitoring of life-threatening symptoms of MCs, mainly 
nephropathy and widespread vasculitis, as well endocrine, metabolic, vasculopathic, and 
neoplastic complica- tions, such as B-cell lymphoma, should be carried out in all patients [33].  
The treatment of MCs is particularly challenging; it is mainly due to the complex 
etiopathogenesis of the disease characterized by the coexistence of chronic HCV infection, 
autoimmune/lymphoprolifera- tive alterations, and immune-complex-related vasculitis [5,33,63]. 
Because of the clinical polymorphism of the disease, clinicians of different medicine 
subspecialties, such as rheumatologists, hepatol- ogists, nephrologists, etc., are generally involved 
in the management of various clinical phenotypes of cryoglobulinemic syndrome. Conse- quently, 
there is not a unanimously accepted therapeutic strategy among various authors [5,6]. In this 
context, the role of rituximab in the therapeutical armamentarium of cryoglobulinemic vasculitis 
is progressively increased in the last decade. The main target of this drug is the B-lymphocyte 
proliferation that represents a crucial step in the complex etiopathogenesis of the disease [9-
12,24-31,34-60]. In HCV- positive individuals, the therapeutical intervention should be directed 
at chronic HCV infection, which may trigger and possibly maintain the disease, the T- and B-
lymphocyte auto-reactivity with prominent clonal B-cell expansion, and finally at the small vessel 
vasculitis due to circulating cryo- and non-cryoprecipitable immune-complexes [5,6,33]. 
According to this pathogenetic cascade, the disease can be treated at different levels by means of 
etiologic, pathogenetic, and/or symptomatic therapies [33]. In HCV-related MCs an attempt at 
HCV eradication by alpha-interferon and ribavirin treatment should be done, mainly in patients 
with clinically relevant liver involvement and/or recent onset of cryoglobulinemic vasculitis [33]. 
The antiviral treatment shows frequent dropouts, including important immune- mediated side 
effects such as peripheral sensory-motor neuropathy, thyroiditis, and rheumatoid-like polyarthritis 
[33]. The lack of HCV eradication, mainly in patients with HCV-genotype 1, or in the presence of 
stabilized self-perpetual autoimmune disorder the beneficial effect observed with the antiviral 
treatment may be weak or transient. With regards the first-line treatment of HCV-related MCs, 
the expert opinions are quite divergent; given the lack of randomized controlled trials for both 
antiviral and immunosuppressive drugs, including rituximab, it is very difficult to define a 
standard therapeutical strategy [6]. The tailoring of treatment by focusing on the single patient's 
clinical history, disease manifestations, and possible co-morbidities is generally the preferred 
approach. In cryoglobulinemic patients with life-threatening manifestations, including B-cell 
neoplasias, and in those with 'essential' MCs the immunomodulating/immunosuppressive 
treatments represent the first-line intervention. As for the classical systemic vasculitides, the 
presence of severe, rapidly progressive vasculitic complications needs combined treatment with 
high-dose steroids, immunosuppressors, and plasma exchange [6,29]. In the setting of 
severe/active, but not life-threatening conditions rituximab might now represent the first option in 
most instances [9-12,24-31,34-60]; conversely, antiviral treatment with pegylated interferon-alpha 
and ribavirin should be employed for more stabilized patients with ongoing HCV infection and 
severe organ involvement, particularly active chronic hepatitis [6,33].  
Some recent clinical studies suggested that sequential or combined antiviral and 
immunosuppressive (rituximab) treatment could represent a rather useful therapeutic strategy in 
patients with active MCs [26,29,30]. The rationale of such aggressive therapy could be 
particularly indicated in HCV-related MCs with major clinical manifestations and/or poor 
response to standard treatments. In many patients with mild to moderate symptoms the use of 
long-term steroid treatment is often responsible for important side effects and co-morbidities, 
mainly in older patients with long-lasting MCs. In these conditions, intermittent rituximab cycles 
may be usefully employed by reducing/avoiding the chronic steroid administration [43].  
 
 
 
7. Conclusions 
 
On the whole, we can affirm that rituximab may be regarded as useful and safe treatment of 
cryoglobulinemic vasculitis; regardless the presence/absence of associated HCV infection. The 
actual role of this drug and its position in the therapeutical strategy, should be confirmed by 
randomized controlled trials. 
 
Take-home messages  
 
• The treatment of MCs is based on etiological, pathogenetic, and/or symptomatic therapies.  
• Among pathogenetic treatments, rituximab is increasingly used during the last decade.  
• Our study shows the efficacy and safety of rituximab in a series 87 MCs patients.  
• Skin lesions, neuropathy, and nephropathy were particularly responsive to rituximab.  
• An updated review of published reports on this topic is done.  
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Anti-muscarinic acetylcholine receptor peptides antibodies in Sjögren's Syndrome: small 
bricks in the mystery 
 
The diagnosis of Sjögren's Syndrome (SS) is still puzzling, and the clinical significance of 
pathogenic autoantibodies remains controversial. Nonetheless, anti-muscarinic acetylcholine type-
3 receptor (anti-M3R) autoantibodies have been shown to be a good serum marker in the disease, 
since the first report from Gao et al (Arthritis Rheum. 2004;50:2615-21). The exact epitope 
against with is directed the autoimmune response is still not clear, thus, he et al assessed the 
clinical correlations of anti-M3R-derived peptide antibodies in patients with SS (Rheumatology 
(Oxford). 2011;50:879-84). In an elegant paper, the authors synthesized four cyclic peptides 
(namely, cyclic1M3R peptide (c1M3RP), c2M3RP, c3M3RP, c4M3RP) and then performed a 
solid-phase immunoassay for M3RP. The results showed that the cyclic 2 M3R peptide had a 
prevalence of 62.2% in patients with SS, significantly higher than that observed in patients with 
rheumatoid arthritis, systemic lupus erythematosus and healthy controls. Furthermore, such 
prevalence was higher in SS patients lacking anti-SSA and anti-SSB antibodies. It could be 
suggested to use this serological marker in addition with anti-SSA and anti-SSB in the diagnosis 
of SS. Furthermore, the anti- c2M3RP antibodies were found to be associated with higher 
ESSDAI score. All these data are a confirmation of an involvement of these autoantibodies in the 
pathogenesis of SS. The test used by He et al. for the detection of anti-c2M3RP should be 
replicated in wider studies, and eventually adopted in the diagnosis and monitoring of SS. 
However, the mechanisms by which these autoantibodies play their role in SS should be one of 
the challenges of the next future research.  
 
 
